Publications by authors named "Mike Chambers"

Claim this Profile
C
Clinical equivalence and non-inferiority within health technology assessment.
Matthew Taylor, Joe Goldbacher, Charlotte Graham, James Mahon, Mike Chambers

Eur J Health Econ· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Statistical Modeling of Disease Progression for Chronic Obstructive Pulmonary Disease Using Data from the ECLIPSE Study.
Alex Exuzides, Chris Colby, Andrew H Briggs, David A Lomas, Maureen P M H Rutten-van Mölken, Mike Chambers

Med Decis Making· May 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development of the Galaxy Chronic Obstructive Pulmonary Disease (COPD) Model Using Data from ECLIPSE: Internal Validation of a Linked-Equations Cohort Model.
Andrew H Briggs, Timothy Baker, Nancy A Risebrough, Mike Chambers, Sebastian Gonzalez-McQuire

Med Decis Making· May 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development of a Conceptual Model of Disease Progression for Use in Economic Modeling of Chronic Obstructive Pulmonary Disease.
Maggie Tabberer, Sebastian Gonzalez-McQuire, Hana Muellerova, Andrew H Briggs, Maureen P M H Rutten-van Mölken, Mike Chambers

Med Decis Making· May 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mortality and drug therapy in patients with chronic obstructive pulmonary disease: a network meta-analysis.
David A Scott, Bethan Woods, Juliette C Thompson, James F Clark, Neil Hawkins, Mike Chambers

BMC Pulm Med· November 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Economic efficiency of genetic screening to inform the use of abacavir sulfate in the treatment of HIV.
Teresa L Kauf, Raymond A Farkouh, Stephanie R Earnshaw, Maria E Watson, Penny Maroudas, Mike G Chambers

Pharmacoeconomics· October 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Predicting EQ-5D values using the SGRQ.
Helen J Starkie, Andrew H Briggs, Mike G Chambers, Paul Jones

Value Health· June 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-effectiveness of fluticasone propionate/salmeterol (500/50 microg) in the treatment of COPD.
Stephanie R Earnshaw, Michele R Wilson, Anand A Dalal, Mike G Chambers, Priti Jhingran

Respir Med· January 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-effectiveness of 123I-FP-CIT SPECT in the differential diagnosis of essential tremor and Parkinson's disease in Italy.
Angelo Antonini, Patrizia Berto, Stefania Lopatriello, Filippo Tamma, Lieven Annemans, Mike Chambers

Mov Disord· November 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacoeconomics in COPD: lessons for the future.
Helen J Starkie, Andrew H Briggs, Mike G Chambers

Int J Chron Obstruct Pulmon Dis· July 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Specialist nurse intervention to reduce unscheduled asthma care in a deprived multiethnic area: the east London randomised controlled trial for high risk asthma (ELECTRA).
Chris Griffiths, Gill Foster, Neil Barnes, Sandra Eldridge, Helen Tate, Mike Chambers

BMJ· January 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis